市場調査レポート

商品コード

1123551

世界の統合失調症治療薬市場：考察と予測 (2028年まで)

Global Schizophrenia Drugs Market Insights, Forecast to 2028

出版日: 2022年09月08日 | 発行: QYResearch

| ページ情報: 英文 131 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,900 769,986円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 7,350 1,154,979円

レポートPDFを5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 9,800 1,539,972円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートは、統合失調症治療薬 (Schizophrenia Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

統合失調症治療薬の製品概要
市場：タイプ別
- 世界の統合失調症治療薬の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
- Oral Antipsychotics
- Injectable Antipsychotics
市場：アプリケーション別
- 世界の統合失調症治療薬の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
- Hospital
- Clinic
調査目的
対象期間

第2章レポート概要

世界の統合失調症治療薬の販売推定および予測 2017-2028
世界の統合失調症治療薬の収益推定および予測 2017-2028
世界の統合失調症治療薬の収益：地域別: 2017 VS 2021 VS 2028
世界の統合失調症治療薬の販売：地域別
- 世界の統合失調症治療薬の販売：地域別 (2017-2022)
- 世界の販売統合失調症治療薬：地域別 (2023-2028)
世界の統合失調症治療薬の収益：地域別
- 世界の統合失調症治療薬の収益：地域別 (2017-2022)
- 世界の統合失調症治療薬の収益：地域別 (2023-2028)
北米
欧州
アジア太平洋地域
ラテンアメリカ
中東・アフリカ

第3章競合：メーカー別

世界の統合失調症治療薬の販売：メーカー別
- 世界の統合失調症治療薬の上位メーカー：販売別 (2017-2022)
- 世界の統合失調症治療薬の販売市場シェア：メーカー別 (2017-2022)
- 世界の上位10・上位5メーカー：統合失調症治療薬2021
世界の統合失調症治療薬の収益：メーカー別
- 世界の統合失調症治療薬の収益：メーカー別 (2017-2022)
- 世界の統合失調症治療薬の収益市場シェア：メーカー別 (2017-2022)
- 世界の上位10・上位5企業：統合失調症治療薬の収益 2021
世界の統合失調症治療薬の販売価格：メーカー別 (2017-2022)
競合情勢の分析
- メーカーの市場集中度 (CR5 and HHI)
- 世界の統合失調症治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
- 世界の統合失調症治療薬のメーカーの地理的分布
M&A, 拡張計画

第4章市場規模：タイプ別

世界の統合失調症治療薬の販売：タイプ別
- 世界の統合失調症治療薬の販売実績：タイプ別 (2017-2022)
- 世界の統合失調症治療薬の販売予測：タイプ別 (2023-2028)
- 世界の統合失調症治療薬の販売市場シェア：タイプ別 (2017-2028)
世界の統合失調症治療薬の収益：タイプ別
- 世界の統合失調症治療薬の収益実績：タイプ別 (2017-2022)
- 世界の統合失調症治療薬の収益予測：タイプ別 (2023-2028)
- 世界の統合失調症治療薬の収益市場シェア：タイプ別 (2017-2028)
世界の統合失調症治療薬の価格：タイプ別
- 世界の統合失調症治療薬の価格：タイプ別 (2017-2022)
- 世界の統合失調症治療薬の価格予測：タイプ別 (2023-2028)

第5章市場規模：アプリケーション別

世界の統合失調症治療薬の販売：アプリケーション別
- 世界の統合失調症治療薬の販売実績：アプリケーション別 (2017-2022)
- 世界の統合失調症治療薬の販売予測：アプリケーション別 (2023-2028)
- 世界の統合失調症治療薬の販売市場シェア：アプリケーション別 (2017-2028)
世界の統合失調症治療薬の収益：アプリケーション別
- 世界の統合失調症治療薬の収益実績：アプリケーション別 (2017-2022)
- 世界の統合失調症治療薬の収益予測：アプリケーション別 (2023-2028)
- 世界の統合失調症治療薬の収益市場シェア：アプリケーション別 (2017-2028)
世界の統合失調症治療薬の価格：アプリケーション別
- 世界の統合失調症治療薬の価格：アプリケーション別 (2017-2022)
- 世界の統合失調症治療薬の価格予測：アプリケーション別 (2023-2028)

第6章北米

北米の統合失調症治療薬市場規模：タイプ別
- 北米の統合失調症治療薬の販売：タイプ別 (2017-2028)
- 北米の統合失調症治療薬の収益：タイプ別 (2017-2028)
北米の統合失調症治療薬市場規模：アプリケーション別
- 北米の統合失調症治療薬の販売：アプリケーション別 (2017-2028)
- 北米の統合失調症治療薬の収益：アプリケーション別 (2017-2028)
北米の統合失調症治療薬市場規模：国別
- 北米の統合失調症治療薬の販売：国別 (2017-2028)
- 北米の統合失調症治療薬の収益：国別 (2017-2028)
- 米国
- カナダ

第7章欧州

欧州の統合失調症治療薬市場規模：タイプ別
- 欧州の統合失調症治療薬の販売：タイプ別 (2017-2028)
- 欧州の統合失調症治療薬の収益：タイプ別 (2017-2028)
欧州の統合失調症治療薬市場規模：アプリケーション別
- 欧州の統合失調症治療薬の販売：アプリケーション別 (2017-2028)
- 欧州の統合失調症治療薬の収益：アプリケーション別 (2017-2028)
欧州の統合失調症治療薬市場規模：国別
- 欧州の統合失調症治療薬の販売：国別 (2017-2028)
- 欧州の統合失調症治療薬の収益：国別 (2017-2028)
- ドイツ
- フランス
- 英国
- イタリア
- ロシア

第8章アジア太平洋

アジア太平洋の統合失調症治療薬市場規模：タイプ別
- アジア太平洋の統合失調症治療薬の販売：タイプ別 (2017-2028)
- アジア太平洋の統合失調症治療薬の収益：タイプ別 (2017-2028)
アジア太平洋の統合失調症治療薬市場規模：アプリケーション別
- アジア太平洋の統合失調症治療薬の販売：アプリケーション別 (2017-2028)
- アジア太平洋の統合失調症治療薬の収益：アプリケーション別 (2017-2028)
アジア太平洋の統合失調症治療薬市場規模：地域別
- アジア太平洋の統合失調症治療薬の販売：地域別 (2017-2028)
- アジア太平洋の統合失調症治療薬の収益：地域別 (2017-2028)
- 中国
- 日本
- 韓国
- インド
- オーストラリア
- 台湾
- インドネシア
- タイ
- マレーシア
- フィリピン

第9章ラテンアメリカ

ラテンアメリカの統合失調症治療薬市場規模：タイプ別
- ラテンアメリカの統合失調症治療薬の販売：タイプ別 (2017-2028)
- ラテンアメリカの統合失調症治療薬の収益：タイプ別 (2017-2028)
ラテンアメリカの統合失調症治療薬市場規模：アプリケーション別
- ラテンアメリカの統合失調症治療薬の販売：アプリケーション別 (2017-2028)
- ラテンアメリカの統合失調症治療薬の収益：アプリケーション別 (2017-2028)
ラテンアメリカの統合失調症治療薬市場規模：国別
- ラテンアメリカの統合失調症治療薬の販売：国別 (2017-2028)
- ラテンアメリカの統合失調症治療薬の収益：国別 (2017-2028)
- メキシコ
- ブラジル
- アルゼンチン

第10章中東・アフリカ

中東・アフリカの統合失調症治療薬市場規模：タイプ別
- 中東・アフリカの統合失調症治療薬の販売：タイプ別 (2017-2028)
- 中東・アフリカの統合失調症治療薬の収益：タイプ別 (2017-2028)
中東・アフリカの統合失調症治療薬市場規模：アプリケーション別
- 中東・アフリカの統合失調症治療薬の販売：アプリケーション別 (2017-2028)
- 中東・アフリカの統合失調症治療薬の収益：アプリケーション別 (2017-2028)
中東・アフリカの統合失調症治療薬市場規模：国別
- 中東・アフリカの統合失調症治療薬の販売：国別 (2017-2028)
- 中東・アフリカの統合失調症治療薬の収益：国別 (2017-2028)
- トルコ
- サウジアラビア

第11章企業プロファイル

Johnson & Johnson
Bristol-Myers Squibb
Otsuka Pharma
AstraZeneca
Sumitomo Dainippon
Eli Lilly
Alkermes
Vanda Pharma
Allergan
Pfizer

第12章業界チェーンと販売チャネルの分析

統合失調症治療薬業界チェーン分析
統合失調症治療薬主要原材料分析
- 主要原材料分析
- 原材料の主要サプライヤー
統合失調症治療薬生産形態とプロセス
統合失調症治療薬販売およびマーケティング
- 統合失調症治療薬販売チャネル
- 統合失調症治療薬卸業者
統合失調症治療薬顧客

第13章市場の促進要因, 機会, 課題とリスク要因の分析

統合失調症治療薬業界動向
統合失調症治療薬市場の促進要因
統合失調症治療薬市場の課題
統合失調症治療薬市場の抑制要因

第14章世界の統合失調症治療薬の主な市場調査結果

第15章付録

図表

Table 1. Global Schizophrenia Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Oral Antipsychotics
Table 3. Major Manufacturers of Injectable Antipsychotics
Table 4. Global Schizophrenia Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Schizophrenia Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Schizophrenia Drugs Sales by Region (2017-2022) & (K Units)
Table 7. Global Schizophrenia Drugs Sales Market Share by Region (2017-2022)
Table 8. Global Schizophrenia Drugs Sales by Region (2023-2028) & (K Units)
Table 9. Global Schizophrenia Drugs Sales Market Share by Region (2023-2028)
Table 10. Global Schizophrenia Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Schizophrenia Drugs Revenue Market Share by Region (2017-2022)
Table 12. Global Schizophrenia Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Schizophrenia Drugs Revenue Market Share by Region (2023-2028)
Table 14. Global Schizophrenia Drugs Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Schizophrenia Drugs Sales Share by Manufacturers (2017-2022)
Table 16. Global Schizophrenia Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Schizophrenia Drugs Revenue Share by Manufacturers (2017-2022)
Table 18. Schizophrenia Drugs Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Schizophrenia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Schizophrenia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Schizophrenia Drugs as of 2021)
Table 21. Schizophrenia Drugs Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Schizophrenia Drugs Product Offered
Table 23. Date of Manufacturers Enter into Schizophrenia Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Schizophrenia Drugs Sales by Type (2017-2022) & (K Units)
Table 26. Global Schizophrenia Drugs Sales by Type (2023-2028) & (K Units)
Table 27. Global Schizophrenia Drugs Sales Share by Type (2017-2022)
Table 28. Global Schizophrenia Drugs Sales Share by Type (2023-2028)
Table 29. Global Schizophrenia Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Schizophrenia Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Schizophrenia Drugs Revenue Share by Type (2017-2022)
Table 32. Global Schizophrenia Drugs Revenue Share by Type (2023-2028)
Table 33. Schizophrenia Drugs Price by Type (2017-2022) & (US$/Unit)
Table 34. Global Schizophrenia Drugs Price Forecast by Type (2023-2028) & (US$/Unit)
Table 35. Global Schizophrenia Drugs Sales by Application (2017-2022) & (K Units)
Table 36. Global Schizophrenia Drugs Sales by Application (2023-2028) & (K Units)
Table 37. Global Schizophrenia Drugs Sales Share by Application (2017-2022)
Table 38. Global Schizophrenia Drugs Sales Share by Application (2023-2028)
Table 39. Global Schizophrenia Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Schizophrenia Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Schizophrenia Drugs Revenue Share by Application (2017-2022)
Table 42. Global Schizophrenia Drugs Revenue Share by Application (2023-2028)
Table 43. Schizophrenia Drugs Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Schizophrenia Drugs Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Schizophrenia Drugs Sales by Type (2017-2022) & (K Units)
Table 46. North America Schizophrenia Drugs Sales by Type (2023-2028) & (K Units)
Table 47. North America Schizophrenia Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Schizophrenia Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Schizophrenia Drugs Sales by Application (2017-2022) & (K Units)
Table 50. North America Schizophrenia Drugs Sales by Application (2023-2028) & (K Units)
Table 51. North America Schizophrenia Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Schizophrenia Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Schizophrenia Drugs Sales by Country (2017-2022) & (K Units)
Table 54. North America Schizophrenia Drugs Sales by Country (2023-2028) & (K Units)
Table 55. North America Schizophrenia Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Schizophrenia Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Schizophrenia Drugs Sales by Type (2017-2022) & (K Units)
Table 58. Europe Schizophrenia Drugs Sales by Type (2023-2028) & (K Units)
Table 59. Europe Schizophrenia Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Schizophrenia Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Schizophrenia Drugs Sales by Application (2017-2022) & (K Units)
Table 62. Europe Schizophrenia Drugs Sales by Application (2023-2028) & (K Units)
Table 63. Europe Schizophrenia Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Schizophrenia Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Schizophrenia Drugs Sales by Country (2017-2022) & (K Units)
Table 66. Europe Schizophrenia Drugs Sales by Country (2023-2028) & (K Units)
Table 67. Europe Schizophrenia Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Schizophrenia Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Schizophrenia Drugs Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Schizophrenia Drugs Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Schizophrenia Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Schizophrenia Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Schizophrenia Drugs Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Schizophrenia Drugs Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Schizophrenia Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Schizophrenia Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Schizophrenia Drugs Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Schizophrenia Drugs Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Schizophrenia Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Schizophrenia Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Schizophrenia Drugs Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Schizophrenia Drugs Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Schizophrenia Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Schizophrenia Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Schizophrenia Drugs Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Schizophrenia Drugs Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Schizophrenia Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Schizophrenia Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Schizophrenia Drugs Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Schizophrenia Drugs Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Schizophrenia Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Schizophrenia Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Schizophrenia Drugs Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Schizophrenia Drugs Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Schizophrenia Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Schizophrenia Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Schizophrenia Drugs Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Schizophrenia Drugs Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Schizophrenia Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Schizophrenia Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Schizophrenia Drugs Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Schizophrenia Drugs Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Schizophrenia Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Schizophrenia Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 105. Johnson & Johnson Corporation Information
Table 106. Johnson & Johnson Description and Major Businesses
Table 107. Johnson & Johnson Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. Johnson & Johnson Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Johnson & Johnson Recent Developments
Table 110. Bristol-Myers Squibb Corporation Information
Table 111. Bristol-Myers Squibb Description and Major Businesses
Table 112. Bristol-Myers Squibb Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. Bristol-Myers Squibb Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Bristol-Myers Squibb Recent Developments
Table 115. Otsuka Pharma Corporation Information
Table 116. Otsuka Pharma Description and Major Businesses
Table 117. Otsuka Pharma Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. Otsuka Pharma Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Otsuka Pharma Recent Developments
Table 120. AstraZeneca Corporation Information
Table 121. AstraZeneca Description and Major Businesses
Table 122. AstraZeneca Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. AstraZeneca Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. AstraZeneca Recent Developments
Table 125. Sumitomo Dainippon Corporation Information
Table 126. Sumitomo Dainippon Description and Major Businesses
Table 127. Sumitomo Dainippon Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 128. Sumitomo Dainippon Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Sumitomo Dainippon Recent Developments
Table 130. Eli Lilly Corporation Information
Table 131. Eli Lilly Description and Major Businesses
Table 132. Eli Lilly Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 133. Eli Lilly Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Eli Lilly Recent Developments
Table 135. Alkermes Corporation Information
Table 136. Alkermes Description and Major Businesses
Table 137. Alkermes Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 138. Alkermes Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Alkermes Recent Developments
Table 140. Vanda Pharma Corporation Information
Table 141. Vanda Pharma Description and Major Businesses
Table 142. Vanda Pharma Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 143. Vanda Pharma Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Vanda Pharma Recent Developments
Table 145. Allergan Corporation Information
Table 146. Allergan Description and Major Businesses
Table 147. Allergan Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 148. Allergan Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Allergan Recent Developments
Table 150. Pfizer Corporation Information
Table 151. Pfizer Description and Major Businesses
Table 152. Pfizer Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 153. Pfizer Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Pfizer Recent Developments
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Schizophrenia Drugs Distributors List
Table 158. Schizophrenia Drugs Customers List
Table 159. Schizophrenia Drugs Market Trends
Table 160. Schizophrenia Drugs Market Drivers
Table 161. Schizophrenia Drugs Market Challenges
Table 162. Schizophrenia Drugs Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources

List of Figures

Figure 1. Schizophrenia Drugs Product Picture
Figure 3. Global Schizophrenia Drugs Market Share by Type in 2021 & 2028
Figure 3. Oral Antipsychotics Product Picture
Figure 4. Injectable Antipsychotics Product Picture
Figure 5. Global Schizophrenia Drugs Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Schizophrenia Drugs Report Years Considered
Figure 9. Global Schizophrenia Drugs Sales 2017-2028 (K Units)
Figure 10. Global Schizophrenia Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Schizophrenia Drugs Revenue 2017-2028 (US$ Million)
Figure 12. Global Schizophrenia Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Schizophrenia Drugs Sales Market Share by Region (2017-2022)
Figure 14. Global Schizophrenia Drugs Sales Market Share by Region (2023-2028)
Figure 15. North America Schizophrenia Drugs Sales YoY (2017-2028) & (K Units)
Figure 16. North America Schizophrenia Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Schizophrenia Drugs Sales YoY (2017-2028) & (K Units)
Figure 18. Europe Schizophrenia Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Schizophrenia Drugs Sales YoY (2017-2028) & (K Units)
Figure 20. Asia-Pacific Schizophrenia Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Schizophrenia Drugs Sales YoY (2017-2028) & (K Units)
Figure 22. Latin America Schizophrenia Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Schizophrenia Drugs Sales YoY (2017-2028) & (K Units)
Figure 24. Middle East & Africa Schizophrenia Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Schizophrenia Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Schizophrenia Drugs in the World: Market Share by Schizophrenia Drugs Revenue in 2021
Figure 27. Global Schizophrenia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Schizophrenia Drugs Sales Market Share by Type (2017-2028)
Figure 29. Global Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
Figure 30. Global Schizophrenia Drugs Sales Market Share by Application (2017-2028)
Figure 31. Global Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
Figure 32. North America Schizophrenia Drugs Sales Market Share by Type (2017-2028)
Figure 33. North America Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
Figure 34. North America Schizophrenia Drugs Sales Market Share by Application (2017-2028)
Figure 35. North America Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
Figure 36. North America Schizophrenia Drugs Sales Share by Country (2017-2028)
Figure 37. North America Schizophrenia Drugs Revenue Share by Country (2017-2028)
Figure 38. U.S. Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Schizophrenia Drugs Sales Market Share by Type (2017-2028)
Figure 41. Europe Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
Figure 42. Europe Schizophrenia Drugs Sales Market Share by Application (2017-2028)
Figure 43. Europe Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
Figure 44. Europe Schizophrenia Drugs Sales Share by Country (2017-2028)
Figure 45. Europe Schizophrenia Drugs Revenue Share by Country (2017-2028)
Figure 46. Germany Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. France Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Schizophrenia Drugs Sales Market Share by Type (2017-2028)
Figure 52. Asia Pacific Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
Figure 53. Asia Pacific Schizophrenia Drugs Sales Market Share by Application (2017-2028)
Figure 54. Asia Pacific Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
Figure 55. Asia Pacific Schizophrenia Drugs Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Schizophrenia Drugs Revenue Share by Region (2017-2028)
Figure 57. China Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 60. India Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. Taiwan Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Philippines Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Schizophrenia Drugs Sales Market Share by Type (2017-2028)
Figure 68. Latin America Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Schizophrenia Drugs Sales Market Share by Application (2017-2028)
Figure 70. Latin America Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Schizophrenia Drugs Sales Share by Country (2017-2028)
Figure 72. Latin America Schizophrenia Drugs Revenue Share by Country (2017-2028)
Figure 73. Mexico Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Schizophrenia Drugs Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Schizophrenia Drugs Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Schizophrenia Drugs Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Schizophrenia Drugs Revenue Share by Country (2017-2028)
Figure 82. Turkey Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 84. UAE Schizophrenia Drugs Revenue (2017-2028) & (US$ Million)
Figure 85. Schizophrenia Drugs Value Chain
Figure 86. Schizophrenia Drugs Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

This research report focuses on the Schizophrenia Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

1 Study Coverage

1.1 Schizophrenia Drugs Product Introduction
1.2 Market by Type
- 1.2.1 Global Schizophrenia Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
- 1.2.2 Oral Antipsychotics
- 1.2.3 Injectable Antipsychotics
1.3 Market by Application
- 1.3.1 Global Schizophrenia Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Hospital
- 1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary

2.1 Global Schizophrenia Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Schizophrenia Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Schizophrenia Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Schizophrenia Drugs Sales by Region
- 2.4.1 Global Schizophrenia Drugs Sales by Region (2017-2022)
- 2.4.2 Global Sales Schizophrenia Drugs by Region (2023-2028)
2.5 Global Schizophrenia Drugs Revenue by Region
- 2.5.1 Global Schizophrenia Drugs Revenue by Region (2017-2022)
- 2.5.2 Global Schizophrenia Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Schizophrenia Drugs Sales by Manufacturers
- 3.1.1 Global Top Schizophrenia Drugs Manufacturers by Sales (2017-2022)
- 3.1.2 Global Schizophrenia Drugs Sales Market Share by Manufacturers (2017-2022)
- 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Schizophrenia Drugs in 2021
3.2 Global Schizophrenia Drugs Revenue by Manufacturers
- 3.2.1 Global Schizophrenia Drugs Revenue by Manufacturers (2017-2022)
- 3.2.2 Global Schizophrenia Drugs Revenue Market Share by Manufacturers (2017-2022)
- 3.2.3 Global Top 10 and Top 5 Companies by Schizophrenia Drugs Revenue in 2021
3.3 Global Schizophrenia Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
- 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Schizophrenia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4.3 Global Schizophrenia Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Schizophrenia Drugs Sales by Type
- 4.1.1 Global Schizophrenia Drugs Historical Sales by Type (2017-2022)
- 4.1.2 Global Schizophrenia Drugs Forecasted Sales by Type (2023-2028)
- 4.1.3 Global Schizophrenia Drugs Sales Market Share by Type (2017-2028)
4.2 Global Schizophrenia Drugs Revenue by Type
- 4.2.1 Global Schizophrenia Drugs Historical Revenue by Type (2017-2022)
- 4.2.2 Global Schizophrenia Drugs Forecasted Revenue by Type (2023-2028)
- 4.2.3 Global Schizophrenia Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Schizophrenia Drugs Price by Type
- 4.3.1 Global Schizophrenia Drugs Price by Type (2017-2022)
- 4.3.2 Global Schizophrenia Drugs Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Schizophrenia Drugs Sales by Application
- 5.1.1 Global Schizophrenia Drugs Historical Sales by Application (2017-2022)
- 5.1.2 Global Schizophrenia Drugs Forecasted Sales by Application (2023-2028)
- 5.1.3 Global Schizophrenia Drugs Sales Market Share by Application (2017-2028)
5.2 Global Schizophrenia Drugs Revenue by Application
- 5.2.1 Global Schizophrenia Drugs Historical Revenue by Application (2017-2022)
- 5.2.2 Global Schizophrenia Drugs Forecasted Revenue by Application (2023-2028)
- 5.2.3 Global Schizophrenia Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Schizophrenia Drugs Price by Application
- 5.3.1 Global Schizophrenia Drugs Price by Application (2017-2022)
- 5.3.2 Global Schizophrenia Drugs Price Forecast by Application (2023-2028)

6 North America

6.1 North America Schizophrenia Drugs Market Size by Type
- 6.1.1 North America Schizophrenia Drugs Sales by Type (2017-2028)
- 6.1.2 North America Schizophrenia Drugs Revenue by Type (2017-2028)
6.2 North America Schizophrenia Drugs Market Size by Application
- 6.2.1 North America Schizophrenia Drugs Sales by Application (2017-2028)
- 6.2.2 North America Schizophrenia Drugs Revenue by Application (2017-2028)
6.3 North America Schizophrenia Drugs Market Size by Country
- 6.3.1 North America Schizophrenia Drugs Sales by Country (2017-2028)
- 6.3.2 North America Schizophrenia Drugs Revenue by Country (2017-2028)
- 6.3.3 U.S.
- 6.3.4 Canada

7 Europe

7.1 Europe Schizophrenia Drugs Market Size by Type
- 7.1.1 Europe Schizophrenia Drugs Sales by Type (2017-2028)
- 7.1.2 Europe Schizophrenia Drugs Revenue by Type (2017-2028)
7.2 Europe Schizophrenia Drugs Market Size by Application
- 7.2.1 Europe Schizophrenia Drugs Sales by Application (2017-2028)
- 7.2.2 Europe Schizophrenia Drugs Revenue by Application (2017-2028)
7.3 Europe Schizophrenia Drugs Market Size by Country
- 7.3.1 Europe Schizophrenia Drugs Sales by Country (2017-2028)
- 7.3.2 Europe Schizophrenia Drugs Revenue by Country (2017-2028)
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 U.K.
- 7.3.6 Italy
- 7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Schizophrenia Drugs Market Size by Type
- 8.1.1 Asia Pacific Schizophrenia Drugs Sales by Type (2017-2028)
- 8.1.2 Asia Pacific Schizophrenia Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Schizophrenia Drugs Market Size by Application
- 8.2.1 Asia Pacific Schizophrenia Drugs Sales by Application (2017-2028)
- 8.2.2 Asia Pacific Schizophrenia Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Schizophrenia Drugs Market Size by Region
- 8.3.1 Asia Pacific Schizophrenia Drugs Sales by Region (2017-2028)
- 8.3.2 Asia Pacific Schizophrenia Drugs Revenue by Region (2017-2028)
- 8.3.3 China
- 8.3.4 Japan
- 8.3.5 South Korea
- 8.3.6 India
- 8.3.7 Australia
- 8.3.8 Taiwan
- 8.3.9 Indonesia
- 8.3.10 Thailand
- 8.3.11 Malaysia
- 8.3.12 Philippines

9 Latin America

9.1 Latin America Schizophrenia Drugs Market Size by Type
- 9.1.1 Latin America Schizophrenia Drugs Sales by Type (2017-2028)
- 9.1.2 Latin America Schizophrenia Drugs Revenue by Type (2017-2028)
9.2 Latin America Schizophrenia Drugs Market Size by Application
- 9.2.1 Latin America Schizophrenia Drugs Sales by Application (2017-2028)
- 9.2.2 Latin America Schizophrenia Drugs Revenue by Application (2017-2028)
9.3 Latin America Schizophrenia Drugs Market Size by Country
- 9.3.1 Latin America Schizophrenia Drugs Sales by Country (2017-2028)
- 9.3.2 Latin America Schizophrenia Drugs Revenue by Country (2017-2028)
- 9.3.3 Mexico
- 9.3.4 Brazil
- 9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Schizophrenia Drugs Market Size by Type
- 10.1.1 Middle East and Africa Schizophrenia Drugs Sales by Type (2017-2028)
- 10.1.2 Middle East and Africa Schizophrenia Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Schizophrenia Drugs Market Size by Application
- 10.2.1 Middle East and Africa Schizophrenia Drugs Sales by Application (2017-2028)
- 10.2.2 Middle East and Africa Schizophrenia Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Schizophrenia Drugs Market Size by Country
- 10.3.1 Middle East and Africa Schizophrenia Drugs Sales by Country (2017-2028)
- 10.3.2 Middle East and Africa Schizophrenia Drugs Revenue by Country (2017-2028)
- 10.3.3 Turkey
- 10.3.4 Saudi Arabia

11 Company Profiles

11.1 Johnson & Johnson
- 11.1.1 Johnson & Johnson Corporation Information
- 11.1.2 Johnson & Johnson Overview
- 11.1.3 Johnson & Johnson Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.1.4 Johnson & Johnson Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.1.5 Johnson & Johnson Recent Developments
11.2 Bristol-Myers Squibb
- 11.2.1 Bristol-Myers Squibb Corporation Information
- 11.2.2 Bristol-Myers Squibb Overview
- 11.2.3 Bristol-Myers Squibb Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.2.4 Bristol-Myers Squibb Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Otsuka Pharma
- 11.3.1 Otsuka Pharma Corporation Information
- 11.3.2 Otsuka Pharma Overview
- 11.3.3 Otsuka Pharma Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.3.4 Otsuka Pharma Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.3.5 Otsuka Pharma Recent Developments
11.4 AstraZeneca
- 11.4.1 AstraZeneca Corporation Information
- 11.4.2 AstraZeneca Overview
- 11.4.3 AstraZeneca Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.4.4 AstraZeneca Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.4.5 AstraZeneca Recent Developments
11.5 Sumitomo Dainippon
- 11.5.1 Sumitomo Dainippon Corporation Information
- 11.5.2 Sumitomo Dainippon Overview
- 11.5.3 Sumitomo Dainippon Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.5.4 Sumitomo Dainippon Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.5.5 Sumitomo Dainippon Recent Developments
11.6 Eli Lilly
- 11.6.1 Eli Lilly Corporation Information
- 11.6.2 Eli Lilly Overview
- 11.6.3 Eli Lilly Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.6.4 Eli Lilly Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.6.5 Eli Lilly Recent Developments
11.7 Alkermes
- 11.7.1 Alkermes Corporation Information
- 11.7.2 Alkermes Overview
- 11.7.3 Alkermes Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.7.4 Alkermes Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.7.5 Alkermes Recent Developments
11.8 Vanda Pharma
- 11.8.1 Vanda Pharma Corporation Information
- 11.8.2 Vanda Pharma Overview
- 11.8.3 Vanda Pharma Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.8.4 Vanda Pharma Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.8.5 Vanda Pharma Recent Developments
11.9 Allergan
- 11.9.1 Allergan Corporation Information
- 11.9.2 Allergan Overview
- 11.9.3 Allergan Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.9.4 Allergan Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.9.5 Allergan Recent Developments
11.10 Pfizer
- 11.10.1 Pfizer Corporation Information
- 11.10.2 Pfizer Overview
- 11.10.3 Pfizer Schizophrenia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.10.4 Pfizer Schizophrenia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
- 11.10.5 Pfizer Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Schizophrenia Drugs Industry Chain Analysis
12.2 Schizophrenia Drugs Key Raw Materials
- 12.2.1 Key Raw Materials
- 12.2.2 Raw Materials Key Suppliers
12.3 Schizophrenia Drugs Production Mode & Process
12.4 Schizophrenia Drugs Sales and Marketing
- 12.4.1 Schizophrenia Drugs Sales Channels
- 12.4.2 Schizophrenia Drugs Distributors
12.5 Schizophrenia Drugs Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Schizophrenia Drugs Industry Trends
13.2 Schizophrenia Drugs Market Drivers
13.3 Schizophrenia Drugs Market Challenges
13.4 Schizophrenia Drugs Market Restraints

14 Key Findings in The Global Schizophrenia Drugs Study

15 Appendix

15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

世界の統合失調症治療薬市場：考察と予測 (2028年まで)

Global Schizophrenia Drugs Market Insights, Forecast to 2028

目次

第1章調査対象

第2章レポート概要

第3章競合：メーカー別

第4章市場規模：タイプ別

第5章市場規模：アプリケーション別

第6章北米

第7章欧州

第8章アジア太平洋

第9章ラテンアメリカ

第10章中東・アフリカ

第11章企業プロファイル

第12章業界チェーンと販売チャネルの分析

第13章市場の促進要因, 機会, 課題とリスク要因の分析

第14章世界の統合失調症治療薬の主な市場調査結果

第15章付録

List of Figures

TABLE OF CONTENTS

1 Study Coverage

2 Executive Summary

3 Competition by Manufacturers

4 Market Size by Type

5 Market Size by Application

6 North America

7 Europe

8 Asia Pacific

9 Latin America

10 Middle East and Africa

11 Company Profiles

12 Industry Chain and Sales Channels Analysis

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

14 Key Findings in The Global Schizophrenia Drugs Study

15 Appendix

世界の統合失調症治療薬市場：考察と予測 (2028年まで)

Global Schizophrenia Drugs Market Insights, Forecast to 2028

目次

第1章 調査対象

第2章 レポート概要

第3章 競合：メーカー別

第4章 市場規模：タイプ別

第5章 市場規模：アプリケーション別

第6章 北米

第7章 欧州

第8章 アジア太平洋

第9章 ラテンアメリカ

第10章 中東・アフリカ

第11章 企業プロファイル

第12章 業界チェーンと販売チャネルの分析

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

第14章 世界の統合失調症治療薬の主な市場調査結果

第15章 付録

List of Figures

TABLE OF CONTENTS

1 Study Coverage

2 Executive Summary

3 Competition by Manufacturers

4 Market Size by Type

5 Market Size by Application

6 North America

7 Europe

8 Asia Pacific

9 Latin America

10 Middle East and Africa

11 Company Profiles

12 Industry Chain and Sales Channels Analysis

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

14 Key Findings in The Global Schizophrenia Drugs Study

15 Appendix

第1章調査対象

第2章レポート概要

第3章競合：メーカー別

第4章市場規模：タイプ別

第5章市場規模：アプリケーション別

第6章北米

第7章欧州

第8章アジア太平洋

第9章ラテンアメリカ

第10章中東・アフリカ

第11章企業プロファイル

第12章業界チェーンと販売チャネルの分析

第13章市場の促進要因, 機会, 課題とリスク要因の分析

第14章世界の統合失調症治療薬の主な市場調査結果

第15章付録